Last €46.47 EUR
Change Today +0.151 / 0.33%
Volume 655.0
LLY On Other Exchanges
New York
SIX Swiss Ex
Sao Paulo
EN Paris
As of 9:33 AM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/25/14 - €48.20
52 Week Low
10/8/13 - €35.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency, as well as provides anti-infectives. Its neuroscience products treat major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and brain imaging of beta-amyloid neuritic plaques. The company’s oncology products treat pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as malignant pleural mesothelioma; and cardiovascular products are used to treat erectile dysfunction and benign prostatic hyperplasia, and pulmonary arterial hypertension, as well as to reduce thrombotic cardiovascular events and as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to enhance milk productivity in dairy cows; anticoccidial agents; and products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections. The company distributes its products through independent wholesale distributors and directly to pharmacies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

37,925 Employees
Last Reported Date: 02/19/14
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $680.7K
Senior Vice President and General Counsel
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2013.

eli lilly & co (LLY) Key Developments

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar(TM)

The U.S. Food and Drug Administration granted tentative approval for Basaglar(TM) (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. Basaglar is not recommended for the treatment of diabetic ketoacidosis. Basaglar is Eli Lilly and Company and Boehringer Ingelheim's basal insulin, which is intended to provide long-lasting blood sugar control in between meals and during the night. Basaglar has the same amino acid sequence as the currently marketed insulin glargine product and was tentatively approved for use with KwikPen(R), a pre-filled dosing device. Basaglar is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin glargine or one of its other ingredients. With a tentative approval, the FDA has determined that Basaglar meets all of the regulatory requirements for approval, but it is subject to an automatic stay of up to 30 months as a result of litigation filed by Sanofi, claiming patent infringement. Under the Drug Price Competition and Patent Term Restoration Act, the FDA cannot give final approval until the end of the 30-month period in mid-2016, unless the court finds in favor of Lilly earlier.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Announce Approving Jardiance Tablets for Adults with Type 2 Diabetes by FDA

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced the U.S. Food and Drug Administration approved Jardiance tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D). JARDIANCE is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine). JARDIANCE, a once-daily, 10 mg or 25 mg tablet, is a sodium glucose co-transporter-2 (SGLT2) inhibitor. JARDIANCE works by blocking the reabsorption of glucose in the kidney, increasing glucose excretion and lowering blood glucose levels in adults with T2D who have elevated blood glucose levels. Patients should not take JARDIANCE if they have severe kidney problems or are on dialysis, or if they are allergic to empagliflozin or any ingredient in JARDIANCE. JARDIANCE can cause some people to have dehydration (the loss of body water and salt), which may lead to a drop in blood pressure, and may cause patients to feel dizzy or faint.

Eli Lilly and Company Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Financial Guidance for the Full Year of 2014

Eli Lilly and Company reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net income of $733.5 million or $0.68 per diluted share on total revenue of $4,935.6 million against net income of $1,206.2 million or $1.11 per diluted share on total revenue of $5,929.7 million a year ago. On Non-GAAP basis, net income of $733.5 million or $0.68 per diluted share on total revenue of $4,935.6 million against net income of $1,254.9 million or $1.16 per diluted share on total revenue of $5,929.7 million a year ago. The revenue decrease was due to a 17% decline in volume; the impact of changes in price and foreign exchange rates on worldwide revenue was negligible. The decreases in net income and earnings per share were driven primarily by lower operating income. For the six months, the company reported net income of $1,461.4 million or $1.36 per diluted share on total revenue of $9,618.7 million against net income of $2,754.2 million or $2.53 per diluted share on total revenue of $11,531.7 million a year ago. On Non-GAAP basis, net income of $1,483.4 million or $1.38 per diluted share on total revenue of $9,618.7 million against net income of $2,502.6 million or $2.30 per diluted share on total revenue of $11,531.7 million a year ago. The company has revised certain elements of its 2014 financial guidance. Full-year 2014 earnings per share are now expected to be in the range of $2.67 to $2.75 on a reported basis. On a non-GAAP basis, full-year earnings per share are still expected to be in the range of $2.72 to $2.80. The company still anticipates revenue of between $19.4 billion and $20.0 billion. Patent expirations have driven a rapid and severe decline in U.S. Cymbalta and U.S. Evista sales. These revenue declines are expected to be partially offset by growth from a portfolio of other current products including Humalog, Trajenta(R), Cialis, Forteo and Alimta, as well as the animal health business and new product launches. In addition, strong revenue growth is expected in China, while a weaker Japanese yen will dampen revenue growth in Japan. The company still anticipates that gross margin as a percent of revenue will be approximately 73% in 2014. The tax rate is still expected to be approximately 19%, assuming a full-year 2014 benefit of the R&D tax credit and other tax provisions up for extension. If these items are not extended, the 2014 tax rate would be approximately 2 percentage points higher. The company still expects net income to be at least $2.9 billion and still expects operating cash flow to be at least $4.0 billion. Operating cash flows are still expected to be sufficient to pay the company's dividend of approximately $2.1 billion, allow for capital expenditures that are now expected to be approximately $1.2 billion, and fund certain business development activity and share repurchases.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:GR €46.47 EUR +0.151

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $54.97 USD -0.32
Amgen Inc $132.48 USD -0.54
AstraZeneca PLC 4,285 GBp +46.50
Baxter International Inc $75.30 USD +0.1698
Bristol-Myers Squibb Co $50.00 USD -0.30
View Industry Companies

Industry Analysis


Industry Average

Valuation LLY Industry Range
Price/Earnings 19.8x
Price/Sales 3.1x
Price/Book 3.7x
Price/Cash Flow 20.5x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at